Newsbenzinga
Liminatus Pharma Engages Synex Consulting To Support Clinical Development Of IBC101, CD19xCD22 Bivalent CAR-T Cell Therapy Candidate
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…